Vistagen Therapeutics, INC Form 4 insider transactions

Douglas J Williamson, a Director of Vistagen Therapeutics, Inc., received 40,826 shares of common stock on July 29, 2026.

Vistagen Therapeutics Chief Legal Officer Reid G. Adler acquired shares under the company's ESPP.

Vistagen Therapeutics' Chief Financial Officer, Nick B. Tressler, acquired shares under the company's Employee Stock Purchase Plan.

Vistagen Therapeutics Chief Medical Officer Angel S. Angelov received a stock option grant for 150,000 shares.

Vistagen Therapeutics Chief Financial Officer, Nick B. Tressler, has acquired stock options under the company's incentive plan.

Vistagen Therapeutics CEO Shawn Singh received a grant of stock options totaling 75,000 shares with an exercise price of $0.5358.

Vistagen Therapeutics Chief Operating Officer Joshua S. Prince was granted stock options totaling 75,000 shares with an exercise price of $0.5358.

Elissa S. Cote, Chief Corp Development Officer at Vistagen Therapeutics, Inc., was granted incentive stock options for 75,000 shares.

Reid G. Adler, Chief Legal Officer of Vistagen Therapeutics, Inc., was granted stock options for 75,000 shares.

Vistagen Therapeutics' Chief Operating Officer, Joshua S. Prince, acquired 4,386 shares of common stock through the company's Employee Stock Purchase Plan.

Vistagen Therapeutics' Chief Financial Officer, Nick B. Tressler, was granted 150,000 stock options with an exercise price of $4.43, vesting over three years.

Vistagen Therapeutics Director Paul R. Edick received 35,200 stock options with an exercise price of $3.90, vesting over three years.

Vistagen Therapeutics Director Jon S. Saxe received a grant of 17,600 non-qualified stock options with an exercise price of $3.61 per share.

Vistagen Therapeutics Director Mary L. Rotunno was granted 17,600 non-qualified stock options with an exercise price of $3.61, vesting monthly over one year.

Vistagen Therapeutics director Margaret M. FitzPatrick received a grant of 17,600 non-qualified stock options with an exercise price of $3.61 per share.

Vistagen Therapeutics Director Joanne Curley was granted 17,600 non-qualified stock options with an exercise price of $3.61, vesting monthly over one year.

Vistagen Therapeutics Director Ann Michelle Cunningham received a grant of 17,600 non-qualified stock options with an exercise price of $3.61.

Joshua S. Prince, Chief Operating Officer of Vistagen Therapeutics, Inc., is set to acquire 4,882 shares of common stock at $1.70 per share on June 30, 2025, under the company's Employee Stock Purchase Plan.

Vistagen Therapeutics' Chief Legal Officer, Reid G. Adler, acquired 7,541 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan.

Vistagen Therapeutics' Chief Financial Officer, Cynthia Lynn Anderson, has reported a future acquisition of 6,617 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan, effective June 30, 2025.

Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired 7,541 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan.

Vistagen Therapeutics, Inc. has granted 150,000 stock options to its Chief Corporate Development Officer, Elissa S. Cote, as part of her compensation package.

Vistagen Therapeutics, Inc. Chief Financial Officer, Cynthia Lynn Anderson, was granted 100,000 stock options with an exercise price of $1.96, vesting over three years.

Joshua S. Prince, Chief Operating Officer of Vistagen Therapeutics, Inc., was granted 100,000 stock options with an exercise price of $1.96, vesting over a three-year period.

Reid G. Adler, Chief Legal Officer of Vistagen Therapeutics, Inc., was granted 100,000 stock options with an exercise price of $1.96 per share, vesting over three years.

Vistagen Therapeutics, Inc. disclosed that its President and CEO, Shawn Singh, was granted 300,000 stock options with an exercise price of $1.96, vesting over three years.

Vistagen Therapeutics' Chief Operating Officer, Joshua S. Prince, acquired 3,310 shares of common stock through the company's Employee Stock Purchase Plan.

Cynthia Anderson, CFO of Vistagen Therapeutics, acquired 2,592 shares of common stock through the company's Employee Stock Purchase Plan.

Director Jerry B. Gin acquired 14,100 stock options in Vistagen Therapeutics on September 6, 2024, according to a Form 4 filing with the SEC.

Director Jon S. Saxe reports receiving a stock option grant from Vistagen Therapeutics.